FDA lifts clin­i­cal hold on Mus­tang Bio's lentivi­ral gene ther­a­py, paving the way for quick jump in­to piv­otal tri­al

Things were look­ing good for Mus­tang Bio’s MB-107 gene ther­a­py pro­gram. By ear­ly Sep­tem­ber, it had nabbed both rare pe­di­atric dis­ease and or­phan drug des­ig­na­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER